Loading...
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 1...
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362355/ https://ncbi.nlm.nih.gov/pubmed/32589728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001837 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|